Latest news with #NasdaqListingRule5450
Business Insider
5 days ago
- Business
- Business Insider
Carbon Revolution receives noncompliance notification from Nasdaq
Carbon Revolution (CREV) announced that the company has received a notification letter from Nasdaq notifying the company that, based upon the company's annual report on Form 20-F for the fiscal year ended June 30, 2024 which was filed with the SEC on May 14, the company is not in compliance with the minimum stockholder's equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A), which requires companies listed on the Nasdaq Global Select Market to maintain a minimum of $10,000,000 in stockholders' equity for continued listing. Confident Investing Starts Here:
Business Insider
03-05-2025
- Business
- Business Insider
Bon Natural Life receives noncompliance notification from Nasdaq
Bon Natural Life (BON) announced that on April 29, the company received a letter from the listing qualifications staff of Nasdaq, notifying the company that it was not in compliance with Nasdaq Listing Rule 5450, as the company's closing bid price for its Class A ordinary shares, par value $0.001 per share was below $1.00 per share for the prior thirty consecutive business days, which matter serves as a basis for delisting the company's securities from Nasdaq. Additionally, the company's securities had a closing bid of 10c or less for the last ten consecutive trading days, and accordingly, is subject to the provisions under Listing Rule 5810. This serves as an additional basis for delisting, and as such, the company is not eligible for a compliance period. Protect Your Portfolio Against Market Uncertainty
Yahoo
02-05-2025
- Business
- Yahoo
Bon Natural Life Limited Announces Receipt of Nasdaq Delisting Notifications
XI'AN, China, May 02, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ('BON' or the 'Company'), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, announced today that on April 29, 2025, the Company received a letter (the 'Notification Letter') from the Listing Qualifications Staff (the 'Staff') of The Nasdaq Stock Market, LLC ('Nasdaq'), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the 'Minimum Bid Price Requirement'), as the Company's closing bid price for its Class A ordinary shares, par value US$0.001 per share was below $1.00 per share for the prior thirty (30) consecutive business days, which matter serves as a basis for delisting the Company's securities from Nasdaq. Additionally, the Company's securities had a closing bid of $0.10 or less for the last ten consecutive trading days, and accordingly, is subject to the provisions under Listing Rule 5810(c)(3)(A)(iii). This serves as an additional basis for delisting, and as such, the Company is not eligible for a compliance period. On May 1, 2025, the Company received an additional Notification Letter notifying the Company that the Staff has determined to delist the Company's securities pursuant to their discretionary authority under Listing Rule 5101. The Staff's determination was based on public interest concerns in relation to the Company's March 2025 best efforts offering. The Company has filed a notice of appeal and requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff's determination. The appeal will stay delisting of the Company's securities pending the Panel's decision. The Company will evaluate available options to regain compliance with the aforementioned Listing Rules. However, there are no assurances that the Company will be able to regain or maintain compliance or that any such appeal to the Panel will be successful, as applicable. About Bon Natural Life Limited BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit Forward-Looking Statements Certain statements in this announcement are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Investors can identify these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, BON's limited operating history and historical losses; BON's ability to raise additional funding; competition from third parties that are developing or have products for similar uses; BON's ability to obtain, maintain and protect its intellectual property; and BON's expectations regarding its growth, strategy, progress towards its goals. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission. Investor Relations Contact: Cindy Liu | IR Email: bonnatural@ in to access your portfolio
Yahoo
01-05-2025
- Business
- Yahoo
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a share consolidation at a ratio of up to 1-for-50. Following this approval, the Company's Board of Directors authorized a 1-for-7.97 consolidation ratio, which will be implemented as the final share structure. The Company's common shares are expected to begin trading on a post-consolidated basis at the opening of the market on Monday, May 5, 2025. Following the consolidation, the Company's common shares will continue to trade under the symbol "PBM" on the Nasdaq Capital Market, with a new CUSIP number 74449F308. The consolidation is part of the Company's plan to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1) (the "Nasdaq Rule 5450") for continued listing on The Nasdaq Capital Market. At the effective time of the consolidation, every 7.97 issued and outstanding shares of the Company will automatically be combined into one issued and outstanding common share. The number of shares and the exercise price of the Company's outstanding warrants and other equity instruments will also be adjusted proportionately in accordance with their respective terms. As of May 1, 2025, the Company had 4,648,610 common shares issued and outstanding. As a result of the consolidation, the Company will have 583,263 common shares issued and outstanding. No fractional shares will be issued in connection with the consolidation. Any fractional share resulting from the consolidation will be rounded down to the nearest whole share if the fraction is less than one-half of a share and rounded up to the nearest whole share if the fraction is at least one-half of a share. The consolidation affects all shareholders uniformly and will not alter any shareholder's percentage interest in the Company, except for minor adjustments resulting from the treatment of fractional shares. The share consolidation occurs at the registered shareholder level. Shareholders who hold their common shares through brokers, banks, or other nominees (i.e., in 'street name') are considered beneficial holders and may experience a delay in the reflection of the consolidation in their accounts, depending on the procedures of their broker, bank, or nominee. Continental Stock Transfer & Trust Company is acting as the exchange agent and transfer agent for the consolidation. Shareholders holding their shares in book-entry form or through brokerage accounts are not required to take any action. Beneficial holders are encouraged to contact their broker, bank, or custodian with any questions regarding the effect of the share consolidation. About Psyence BioMed: Psyence BioMed aims to be one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. Psyence is dedicated to addressing unmet mental health needs, particularly in palliative care. The name 'Psyence' merges 'psychedelics' and 'science,' reflecting the company's commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders. Learn more at and on LinkedIn. Contact Information for Psyence Biomedical Ltd. Email: ir@ Inquiries: media@ Information: info@ +1 416-477-1708 Investor Contact:Michael KyddInvestor Relations Advisormichael@ Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may relate to future financial and operating results, plans, objectives, expectations, and intentions regarding future operations, products, services, and other matters. Words such as "expects," "will," "intends," "believes," "plans," "anticipates," "projects," "targets," and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this communication include statements regarding the timing and implementation of the share consolidation, the continued listing of the Company's securities on Nasdaq, and the anticipated impact of the consolidation. These statements are based on current assumptions and expectations, including that the share consolidation will be completed without delay, and that the Company will continue to meet Nasdaq's ongoing listing standards. There are numerous risks and uncertainties that may cause actual results or performance to differ materially from those expressed or implied in these forward-looking statements, including, but not limited to: (i) delays or challenges in completing the share consolidation; (ii) the Company's ability to maintain compliance with Nasdaq's continued listing standards; (iii) potential volatility in the Company's share price following the consolidation; (iv) changes in the regulatory, competitive, and economic landscape; and (v) risks associated with the Company's development plans and clinical trials. These and other important risks and uncertainties are described in the "Risk Factors" section of the Company's final prospectus (File No. 333-284444), filed with the U.S. Securities and Exchange Commission on January 24, 2025, and in other documents filed by the Company from time to time with the SEC. Actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence Biomed does not undertake any obligation to update or revise forward-looking statements. The Company does not make any medical, treatment, or health benefit claims regarding its proposed products. The U.S. Food and Drug Administration, Health Canada, or similar regulatory bodies have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of such compounds can diagnose, treat, cure, or prevent any disease or condition. Clinical trials and regulatory approvals are required and, if not obtained, may have a material adverse impact on the Company's business. To view the source version of this press release, please visit Sign in to access your portfolio
Business Insider
22-04-2025
- Business
- Business Insider
Cambium Networks receives deficiency notice from Nasdaq
Cambium Networks (CMBM) announced that on April 16, it received an additional delinquency letter from The Nasdaq Stock Market notifying the company that it continues to be out of compliance with Nasdaq's continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1) due to the company's failure to timely file its Form 10-K for the year ended December 31, 2024. This second deficiency notice follows the notice of delinquency received from Nasdaq on April 10, 2024, notifying the company that it has failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
